Leaders in Life Sciences

Leaders in Life Sciences

By Dr. Kesha Chauhan, MDNewsScienceMedicineHealth & FitnessBusiness NewsLife Sciences
Download on the App Store

Leaders in Life Sciences episodes

  • #21 : Pfizer's New Obesity Drug
    Pfizer is heavily investing in its experimental obesity drug, danuglipron, aiming for a once-daily oral pill to compete with the currently dominant injectable weight-loss treatments from Eli Lilly and Novo Nordisk. CEO Albert Bourla expressed cautious optimism, anticipating data from dose-testing studies within months and a potential market entry as the second oral option. While Pfizer is not pursuing acquisitions in the injectable GLP-1 market, they remain open to acquiring other types of obesity treatments. The company's goal is to provide a convenient and competitive alternative in a market projected to reach $150 billion annually by the early 2030s. The unrelated mention of a "Bio Leg" device suggests extraneous information included in the source material.

    Hosted on Acast. See acast.com/privacy for more information.

    4 min
  • #20 : Acquiring Patient Social Networks
    Swoop, an AI-driven healthcare marketing business, acquired MyHealthTeam, a company that runs condition-specific online patient communities1. MyHealthTeam has over 60 communities, some with over 100,000 members, focused on chronic and rare diseases. These communities feature articles, Q&A sections, and patient conversations. Swoop intends to use this acquisition to enable pharmaceutical companies to engage with patients, scale patient reach, and generate first-party data2. Swoop's offerings include marketing to healthcare professionals and consumers, and planning and tracking TV campaigns. The integration of MyHealthTeam into Swoop's business is intended to enhance its marketing capabilities

    Hosted on Acast. See acast.com/privacy for more information.

    5 min
  • #19 : RSV Vaccines To Include New Warning


    The FDA will require GSK and Pfizer to include a warning about the risk of Guillain-Barré syndrome (GBS) on the labels of their RSV vaccines, Arexvy and Abrysvo, respectively. This decision was made after a postmarketing study showed an increased risk of GBS within 42 days of vaccination. The FDA estimates nine cases of GBS per million doses of Abrysvo and seven cases per million doses of Arexvy in adults 65 and older. Although a causal relationship hasn't been established, the FDA notes that the benefits of the vaccines still outweigh the risks. GSK reports that over 9 million people have received Arexvy with an acceptable safety profile.


    Hosted on Acast. See acast.com/privacy for more information.

    5 min
  • #18: The Future of Pharma Marketing
    The future of pharmaceutical marketing is poised for significant change, driven by technological advancements, a focus on the patient, and sustainability. The integration of cutting-edge technologies like AI, machine learning, and blockchain will enable personalized marketing strategies and enhance data management. A patient-centric approach will engage patients as active participants in their healthcare journeys, with a focus on education and communication. Predictive analytics will help companies anticipate patient needs and tailor solutions. Telehealth and omnichannel marketing will also transform how products are marketed and consumed. Finally, sustainability and corporate social responsibility will be increasingly important, with companies aligning marketing with ethical practices.

    Hosted on Acast. See acast.com/privacy for more information.

    7 min
  • #17 : Ensacove Enters the Lung Cancer Treatment Arena
    The FDA has approved Ensacove (ensartinib), a new second-generation ALK inhibitor, as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC) in patients who have not previously received an ALK inhibitor. Developed by a subsidiary of China's Betta Pharmaceuticals, Ensacove is the first innovative targeted lung cancer drug from a Chinese company to reach the global market. Clinical trial data from the eXalt3 study showed a 44% reduction in the risk of disease progression or death compared to Xalkori. While Ensacove is entering a market with other established ALK inhibitors, including Roche's Alecensa, which showed a 57% reduction in the risk of disease progression or death, and has also been approved for adjuvant treatment and it represents a significant new treatment option for patients.

    Hosted on Acast. See acast.com/privacy for more information.

    6 min
  • #16 : The FDA grants Traditional Marketing Authorization for COVID- 19 Tests
    The FDA initially authorized COVID-19 tests through Emergency Use Authorizations (EUAs) to facilitate their rapid deployment during the pandemic. These tests can continue to be used as long as they are available and not expired. The FDA is now working with test developers to obtain traditional marketing authorization, which involves a more rigorous review process to ensure safety and effectiveness for long-term use. This transition allows tests to be used beyond the time frame allowed under EUAs and is supported by FDA guidance. The FDA considers whether there is reasonable assurance of safety and effectiveness during the traditional premarket review, a higher bar than the EUA process

    Hosted on Acast. See acast.com/privacy for more information.

    5 min
  • #15 : What pharma trends to expect in 2025?
    The pharmaceutical industry is facing significant challenges and must undergo a bold reinvention to ensure its future success. The sector's shareholder returns have been lagging behind the broader market, with a disproportionate amount of value growth concentrated in a small number of companies. This underperformance, combined with disruptive forces, has led CEOs to question the viability of their existing business models. The future of healthcare is shifting towards prevention, personalization, prediction, and point of care necessitating new approaches. Several key trends are shaping the industry, including the exponential impacts of AI, rapid advancements in understanding human biology, pressure to cut drug prices, empowered consumers, and global volatility. These trends are driving changes such as a race to commercialize science, declining economics of traditional business models, new value pools around consumers, and a need for organizational agility. To thrive, pharmaceutical companies must adapt to these changes by focusing on innovation, consumer needs, and the ability to navigate a volatile environment.

    Hosted on Acast. See acast.com/privacy for more information.

    21 min
  • #14: Citius Oncology's LYMPHIR™ Launch Strategy
    Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles.

    Hosted on Acast. See acast.com/privacy for more information.

    4 min
  • #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment
    Johnson & Johnson's Rybrevant and Lazcluze drug combination shows significant improvement in overall survival for patients with EGFR-mutated non-small cell lung cancer compared to the current standard treatment, Tagrisso. This new treatment targets a resistance pathway, offering a potential lifeline for many patients, although it requires infusions and has potential side effects. Full trial results are forthcoming, and the company anticipates substantial sales. The development highlights advances in precision medicine for lung cancer.

    Hosted on Acast. See acast.com/privacy for more information.

    18 min
  • #12: What You need to know about Ozempic and Weight Loss
    This podcast episode discusses Ozempic (semaglutide), a GLP-1 receptor agonist initially used for type 2 diabetes, now gaining popularity for weight loss. The episode details its mechanism of action, effectiveness (showing up to 15% weight loss in trials but with caveats regarding individual responses and potential for weight regain), safety (including common and rare side effects), ethical considerations (addressing societal pressures and the need for holistic care), and cost (highlighting affordability issues and the need for equitable access). The podcast aims to inform healthcare professionals and the public about the drug's benefits, limitations, and broader implications.

    Hosted on Acast. See acast.com/privacy for more information.

    20 min

About Leaders in Life Sciences

From the publisher's feed

The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to…